Peptide Side Effects Cheat Sheet & Who Should Be Cautious
Peptide Side Effects & Who Should Be Cautious: A Quick-Glance Cheat Sheet
TL;DR
- The cautions cluster into three themes - cancer history for the growth and repair compounds, blood sugar for the metabolic ones, then compound-specific flags.
- The GLP-1 class carries a boxed warning for thyroid C-cell tumours (MTC/MEN-2) plus a pancreatitis precaution - semaglutide, tirzepatide and retatrutide alike.
- Melanotan II is the highest-caution entry here - darkening of existing moles and new moles; melanoma or atypical-mole history makes skin surveillance essential.
- PT-141 commonly causes nausea plus a transient blood-pressure rise - flag uncontrolled high blood pressure or cardiovascular disease.
- Compound-specific flags: copper-metabolism disorders for GHK-Cu, pituitary tumour history for the GH secretagogues, immunosuppression for thymosin alpha-1.
- Retatrutide, semax, selank and DSIP are investigational; epithalon is research-grade and carries a theoretical telomerase–cancer caution.
Educational content, not medical advice. This is a general-awareness summary, not an exhaustive list of side effects, and not a substitute for a physician's assessment. Cautions are screening prompts, not absolute bans - many are class-level or theoretical. Whether any compound is right for you is a decision for a supervising physician.
How to read this: "commonly reported" doesn't mean you'll get it - most people tolerate these well, and effects are usually mild and dose-related. The caution column is a list of things to flag to your physician, not reasons you can't ever use something. Superscript numbers link to the source for that row.
Recovery & Repair
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| BPC-157 | Generally well tolerated; occasional mild nausea or headache | Active or recent cancer history (promotes blood-vessel growth) ¹² |
| TB-500 | Fatigue, mild lethargy | Active cancer history; autoimmune conditions |
| KPV | Generally well tolerated; occasional injection-site irritation | Active infection or suppressed immune system ³ |
Skin & Aesthetic
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| GHK-Cu | Skin/injection-site irritation, redness, mild itching | Copper-metabolism disorders (e.g. Wilson's disease) |
Metabolic & Weight (GLP-1 family)
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| Tirzepatide | Nausea, vomiting, diarrhoea, constipation (dose-related) | MTC/MEN-2 personal or family history; pancreatitis history; gastroparesis; diabetics on insulin/sulfonylureas ⁴ |
| Semaglutide | Nausea, diarrhoea, constipation | Same as above ⁴ |
| Retatrutide | Nausea, vomiting, elevated heart rate | Same class cautions; investigational (trial-stage) ⁴ |
| Cagrilintide | Nausea, GI effects (amylin analogue) | Gastroparesis; amplifies GI effects with GLP-1s |
| MOTS-c | Mild fatigue; possible blood-sugar effects | Diabetics / those on glucose-lowering medication |
Growth & Hormonal (GH secretagogues)
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| Tesamorelin | Joint pain, fluid retention, injection-site reactions | Active cancer/cancer history; diabetes/insulin resistance; pituitary tumour history |
| Sermorelin | Flushing, headache | Active cancer; diabetics; heart conditions |
| CJC-1295 (No DAC) | Water retention, flushing, head-rush | Active cancer; diabetics; pituitary tumour history |
| Ipamorelin | Increased appetite, head-rush, mild water retention | Diabetics; cancer history (GH/IGF-1 axis) |
Longevity, Bioregulators & Cognitive
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| SS-31 (Elamipretide) | Generally well tolerated; occasional injection-site reaction | Limited long-term data |
| Epithalon | Limited side-effect data | Telomerase activator → theoretical cancer caution; research-grade ⁵⁶ |
| Thymosin Alpha-1 | Generally well tolerated | Immunosuppressed, transplant, or autoimmune (immunomodulatory) |
| Semax | Well tolerated in research; limited data | Limited safety evidence; investigational |
| Selank | Well tolerated in research; limited data | Limited safety evidence; investigational |
| DSIP | Well tolerated in small studies; limited data | Investigational; mixed evidence |
| NAD+ | Flushing, nausea, chest pressure if infused too fast | Rapid infusion (done slowly to avoid) |
Vitality & Sexual Health
| Peptide | Commonly reported effects | Who should be cautious |
|---|---|---|
| Kisspeptin | Generally well tolerated | Hormone-sensitive conditions (stimulates reproductive-hormone axis) |
| PT-141 (Bremelanotide) | Nausea (common), flushing, headache, transient blood-pressure rise, skin darkening | Uncontrolled high blood pressure; cardiovascular disease ⁷ |
| Melanotan II | Nausea, flushing, darkening of moles / new moles | High caution: history of melanoma or atypical moles; least-characterised safety profile - skin/mole surveillance essential ⁸ |
The bottom line
The cautions cluster around a few predictable themes: cancer history (for the growth-promoting and repair compounds), blood sugar (for the metabolic ones), and a handful of compound-specific flags - copper for GHK-Cu, moles for Melanotan II, blood pressure for PT-141. None of this is cause for alarm; it's the reason physician supervision exists - to match the compound to you, your history, and your goals, rather than self-prescribing from a list.
Cautions are screening prompts, not verdicts. Vivre Labs works the other way round from a list - baseline bloodwork first, independently tested product, and honest labelling of what's approved versus investigational. Book a consult on Telegram, or see how compounds are combined in the goal-based protocols.
References
<a id="ref1"></a>1. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333. - link
<a id="ref2"></a>2. Sikiric P, et al. BPC 157 as a Therapy and Safety Key - Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel). 2025;18(6):928. (PMID 40573323) - link
<a id="ref3"></a>3. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. (PMID 18061177) - link
<a id="ref4"></a>4. GLP-1 / incretin receptor-agonist class - boxed warning for thyroid C-cell tumours (MTC/MEN-2) and pancreatitis precaution: FDA Prescribing Information (semaglutide; tirzepatide). - link
<a id="ref5"></a>5. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. (PMID 12937682) - link
<a id="ref6"></a>6. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. (PMID 41240216) - link
<a id="ref7"></a>7. PT-141 (bremelanotide) - nausea, transient blood-pressure increase, and focal hyperpigmentation per FDA approval/label, NDA 210557. - link
<a id="ref8"></a>8. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide. Life Sci. 1996;58(20):1777–1784 - pharmacology; melanocytic/pigmentary effects underpin the melanoma-surveillance caution. - link
Educational content. Not medical advice and not an exhaustive list of side effects. Cautions are screening prompts, not absolute contraindications, and many are class-level or theoretical. Citations support specific mechanism or label claims; uncited rows reflect general class knowledge. Any use is physician-supervised. For Malaysia-facing care, this information is subject to MAB requirements.
Educational content only. This article is not a prescription, a dose, or a treatment recommendation. Products are sold for research use only - suitability, dosing and monitoring are not set on this site.